| PubChem CID | Drug (INN) | Original Targets (Gene Symbol) | Original Indications |
|---|---|---|---|
| 5566 | trifluoperazine | ADCY1, ADCY3, ADCY4, ADCY6, ADCY8, ADCY9, ADRA1A, ANXA10, ANXA13, ANXA2, ANXA3, ANXA5, ANXA6, CALM1, CALY, DRD2, DRD4, DRD5, F2, FDPS, GRK7, LTB4R, MYH1, MYH2, MYH4, MYH7B, MYL1, MYL12A, MYL2, MYL7, MYL9, MYLK, MYO15A, MYO18B, MYO1C, MYO1D, MYO1E, MYO3A, MYO3B, MYO5B, MYO5C, NDUFAF3, NDUFS5, S100A4, SLC1A5, SLC5A11, SLC7A5, TNNC1, TNNI3, TNNT2 | Antipsychotic Agents, Antiemetics, Alcoholic Intoxication, Chronic, Bipolar Disorder, Catatonia, Hallucinations, Psychotic Disorders, Schizophrenia, Paranoid Schizophrenia, Brain Injuries, Mental deficiency, Alcoholism, Alcohol abuse, Bipolar disorder, Bipolar I disorder, Hallucination, Psychotic disorder, Schizophrenia, paranoid type, Brain injury |
| Drug Name (INN) |
Predicted Drug Target (Uniprot AC) |
Target Prediction Score (Range: 0~1) |
Binding or Not (Positive binding: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | ABLIM2 (Q6H8Q1) | 0.0751 | 0 | - |
| trifluoperazine | SLC13A1 (Q9BZW2) | 0.0751 | 0 | - |
| trifluoperazine | LPAR2 (Q9HBW0) | 0.0751 | 0 | - |
| trifluoperazine | IL12A (P29459) | 0.075 | 0 | - |
| trifluoperazine | Q28044 | 0.075 | 0 | - |
| trifluoperazine | NR2F1 (P10589) | 0.0748 | 0 | - |
| trifluoperazine | SLC22A12 (Q96S37) | 0.0744 | 0 | - |
| trifluoperazine | P08483 | 0.0743 | 0 | - |
| trifluoperazine | GPX5 (O75715) | 0.0742 | 0 | - |
| trifluoperazine | Q89ZI2 | 0.0742 | 0 | - |
| trifluoperazine | NR1I2 (O75469) | 0.074 | 0 | - |
| trifluoperazine | PSMB2 (P49721) | 0.0739 | 0 | - |
| trifluoperazine | PLG (P00747) | 0.0738 | 0 | - |
| trifluoperazine | PARP2 (Q9UGN5) | 0.0738 | 0 | - |
| trifluoperazine | NGFR (P08138) | 0.0738 | 0 | - |
| trifluoperazine | CDH5 (P33151) | 0.0737 | 0 | - |
| trifluoperazine | PRKAB1 (Q9Y478) | 0.0736 | 0 | - |
| trifluoperazine | NTSR2 (O95665) | 0.0735 | 0 | - |
| trifluoperazine | LIPG (Q9Y5X9) | 0.0735 | 0 | - |
| trifluoperazine | FIP1L1 (Q6UN15) | 0.0735 | 0 | - |
| trifluoperazine | HOXA10 (P31260) | 0.0734 | 0 | - |
| trifluoperazine | CCND2 (P30279) | 0.0734 | 0 | - |
| trifluoperazine | ND3 (P03897) | 0.0732 | 0 | - |
| trifluoperazine | Q69091 | 0.0731 | 0 | - |
| trifluoperazine | P55859 | 0.0729 | 0 | - |
| trifluoperazine | Q62758 | 0.0727 | 0 | - |
| trifluoperazine | O09028 | 0.0727 | 0 | - |
| trifluoperazine | ABLIM1 (O14639) | 0.0724 | 0 | - |
| trifluoperazine | GABRA3 (P34903) | 0.0724 | 0 | - |
| trifluoperazine | ADA (P00813) | 0.0722 | 0 | - |
| trifluoperazine | IAPP (P10997) | 0.0722 | 0 | - |
| trifluoperazine | ACADSB (P45954) | 0.0721 | 0 | - |
| trifluoperazine | Q57P83 | 0.072 | 0 | - |
| trifluoperazine | BGLAP (P02818) | 0.072 | 0 | - |
| trifluoperazine | ABRACL (Q9P1F3) | 0.0719 | 0 | - |
| trifluoperazine | Q9X0N8 | 0.0719 | 0 | - |
| trifluoperazine | HCAR1 (Q9BXC0) | 0.0718 | 0 | - |
| trifluoperazine | BAAT (Q14032) | 0.0718 | 0 | - |
| trifluoperazine | P07515 | 0.0718 | 0 | - |
| trifluoperazine | LRRK2 (Q5S007) | 0.0717 | 0 | - |
| trifluoperazine | SLC1A4 (P43007) | 0.0716 | 0 | - |
| trifluoperazine | Q9JJ16 | 0.0716 | 0 | - |
| trifluoperazine | HTR3C (Q8WXA8) | 0.0715 | 0 | - |
| trifluoperazine | HDAC11 (Q96DB2) | 0.0715 | 0 | - |
| trifluoperazine | IL21 (Q9HBE4) | 0.0713 | 0 | - |
| trifluoperazine | HTR2B (P41595) | 0.0713 | 0 | - |
| trifluoperazine | NDUFS1 (P28331) | 0.0712 | 0 | - |
| trifluoperazine | SRD5A2 (P31213) | 0.0711 | 0 | - |
| trifluoperazine | CHRNA1 (P02708) | 0.071 | 0 | - |
| trifluoperazine | CA4 (P22748) | 0.071 | 0 | - |
| Drug (INN) |
Drug Mechanism (Gene ontology) |
Mechanism Score (Range: 0~1) |
Positive or not (Positive: 1) |
|---|---|---|---|
| trifluoperazine | GO:0006281 DNA repair | 1 | 1 |
| trifluoperazine | GO:0031570 DNA integrity checkpoint | 1 | 1 |
| trifluoperazine | GO:0007049 cell cycle | 0.875 | 1 |
| trifluoperazine | GO:0008283 cell population proliferation (viability) | 0.7 | 1 |
| trifluoperazine | GO:0071456 cellular response to hypoxia | 0.3333 | 0 |
| trifluoperazine | GO:0001525 angiogenesis | 0.2857 | 0 |
| trifluoperazine | GO:0008283 cell population proliferation | 0.25 | 0 |
| trifluoperazine | GO:0006954 inflammatory response | 0.2 | 0 |
| trifluoperazine | GO:0008219 cell death | 0.0625 | 0 |
| trifluoperazine | GO:0006096 glycolytic process | 0 | 0 |
| trifluoperazine | GO:0016477 cell migration | 0 | 0 |
| trifluoperazine | GO:0001837 epithelial to mesenchymal transition | 0 | 0 |
| trifluoperazine | GO:0002418 immune response to tumor cell | 0 | 0 |
| trifluoperazine | GO:0010833 telomere maintenance via telomere lengthening | 0 | 0 |
| trifluoperazine | GO:0001570 vasculogenesis | 0 | 0 |
| trifluoperazine | GO:0007155 cell adhesion | 0 | 0 |
| trifluoperazine | GO:0016049 cell growth | 0 | 0 |
| trifluoperazine | GO:0006915 apoptotic process | 0 | 0 |
| Drug (INN) |
Cancer Type | Indication Score (Range: 0~1) |
Cancer Drug or Not (Positive indication: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | Cancer(general) | 0.6236 | 0 | - |